Compare Amylx Pharmaceuticals Inc (AMLX) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Monster Beverage Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Monster Beverage Corp trades at $45.86 (market cap $89.56B). The key difference: Monster Beverage Corp is far larger — about 35.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | MNST | |
|---|---|---|
Market Cap | $2.53B | $89.56B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $49.97 |
52-Week Low | $7.82 | $30.86 |
Enterprise Value | $2.28B | $87.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Monster Beverage (MNST) trades at $45.18, down 4.04% in the last 24 hours, with a bearish technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.60 EPS and record sales of $2.54 billion, driven by international growth. Financials show robust revenue growth from $8.29 billion in 2025 to a projected $9.2 billion in 2026, with net income margins above 23%. A 2-for-1 stock split is scheduled for August 11, 2026.
Outlook remains positive due to consistent earnings beats and global expansion, but high valuation ratios like a P/E of 41.83 pose risks. Analyst consensus is bullish with a $51.14 price target, though competition and economic sensitivity could pressure margins. Investors should weigh growth potential against premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
